Anthem Biosciences, an India-based CDMO, submitted a filing (PDF) at the end of 2024 to announce its plans for a 33.95 ...

Following a fresh round of job cuts in December, CDMO National Resilience is carrying its downsizing efforts into 2025. | ...

If innovative cancer therapies were the top launches to watch in 2024, this year’s high-profile biopharma debuts is slated to ...

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...

Eric Peacock, co-founder and CEO of MyHealthTeam, framed the merger as beneficial for patients, too, saying in a statement ...

Alongside Kosinski’s appointment, FleishmanHillard’s announcement this week included news of three more hires within the health and life sciences team: John Gisborne as global head of strategic client ...

The new name draws from the company’s nearly two decades of work in ryanodine receptor (RyR) biology, which it has used to ...

After holding leadership positions at contract manufacturers Patheon and Thermo Fisher Scientific, working in the food and ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. On this page, we're recording the regulatory progress of in-market products, including expansions into key geographies and ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

With COVID vaccine sales in the doldrums and a respiratory syncytial virus (RSV) vaccine market in “contraction”, Moderna CEO ...